Legend Biotech Corp. · NASDAQ:LEGN
Legend Biotech — Q2 2023 Earnings Presentation
16 slides from Legend Biotech's earnings presentation, Aug 15, 2023
Slide 1: Second Quarter 2023 Financial Results & Corporate Update
August 15, 2023 Second Quarter 2023 Financial Results & Corporate Update This presentation is for investor relations purposes only - Not for product promotional purposes 1
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation has been prepared by Legend Biotech Corporation (“Legend Biotech” or the “Company”) solely for information purpose and does not contain all relevant information relating to the Company. The safety and efficacy of the agents and/or uses under investigation
Slide 3: Agenda
1 Opening Remarks 2 Q2 2023 Performance Overview Agenda 3 4 CARTITUDE Clinical Development Program Update Pipeline Progress 5 Financial Performance 6 Outlook: 2023 and Beyond 7 Q&A This presentation is for investor relations purposes only - Not for product promotional purposes 3
Slide 4: Opening Remarks
Opening Remarks Ying Huang Lori Macomber Chief Executive Officer Chief Financial Officer This presentation is for investor relations purposes only - Not for product promotional purposes 4
Slide 5: Q2 2023 Performance
Q2 2023 Performance CARVYKTI® NET SALES ($MM) EPS Q/Q Q2 2023 Y/Y Change Q2 2023 Q2 2022 Y/Y Change Change -0.57 -0.62 -8% U.S. 114 63% 375% Ex-U.S. 3 50% N/A 1H 2023 1H 2022 Y/Y Change Global 117 63% 388% -0.91 -0.73 25% TOTAL REVENUE ($MM) Q2 2023 and Recent Highlights (order) → Submissions made t
Slide 6: Updated Clinical Profile for Cilta-cel from ASCO 2023
Updated Clinical Profile for Cilta-cel from ASCO 2023 CARTITUDE-4 CARTITUDE-4 LEGEND-2a CARTITUDE-1 Intent-to-treat (n=208)b As-Treated (n=176)b Median number of prior LOT 3 6 2 2 Median follow-up (mo) 65 36 16 16 Efficacy ORR 88% 98% 85% 99% ≥CR 73% 83% 73% 86% 12mo PFS ~70%c 76% 76% 90% mPFS (mo)
Slide 7: Near-Term Label Expansion Potential: Cilta-cel
Near-Term Label Expansion Potential: Cilta-cel Submissions Were Accepted by U.S. FDA and EMA for Expanded Use of CARVYKTI® Heavily Pre-Treated for Multiple Myeloma Earlier Lines for Multiple Myeloma CILTA-CEL HOLDS POTENTIAL TO TRANSFORM MM TREATMENT PARADIGM → Approved by the U.S. FDA for the treat
Slide 8: CARVYKTI Uptake Continues
CARVYKTI® Uptake Continues Continued market penetration, new indications and healthier populations represent significant opportunity for continued growth CARVYKTI® Net Product Sales ($MM) YoY Growth QoQ Growth U.S. 375% 63% +388% growth vs Q2’22 ex-U.S. N/A 50% 120 3 Global 388% 63% 100 80 → U.S. Qo
Slide 9: Our Pipeline
Our Pipeline Global US China PRECLINICAL PHASE 1 PHASE 2 PHASE 3 GASTRIC, GASTRIC & NSCLC RRMM (BCMA)* ESOPHAGEAL & RRMM (BCMA) ESOPHAGEAL & RRMM (BCMA)* 1-3 Prior Lines (GPC3) PANCREATIC† LEGEND-2† PANCREATIC‡ CARTIFAN-1 CARTITUDE-4 Autologous (CLAUDIN 18.2) Autologous CAR-T (CLAUDIN 18.2) Autologo
Slide 10: 2023 2Q and 1H Financial Highlights
2023 2Q and 1H Financial Highlights Total Revenue ($MM) Net Loss (in $MM) EPS (in $) 80 -0.54 -190 +513% 70 -191 -0.55 -193 -0.57 60 -192 -0.56 -8% -193 -0.57 50 -194 -199 -0.58 -0.62 40 -195 73 -196 -0.59 30 -0.6 -197 20 +3% -0.61 -198 10 -199 -0.62 12 0 -200 -0.63 Q2 2022 Q2 2023 Q2 2022 Q2 2023 Q
Slide 11: 2023 2Q and 1H Financial Summary
2023 2Q and 1H Financial Summary ($MM) June 30, 2023 March 31, 2023 Dec 31, 2022 • Raised $785M in April Cash and Cash Equivalents, Time and May, including 1,519 854 1,026 Deposits, and Short-Term Investments $235M in PIPEs, $350M in a Registered ($MM) 2Q 2023 2Q 2022 Y/Y change 1H 2023 1H 2022 Y/Y
Slide 12: Focused Investments in Pipeline and Development
Focused Investments in Pipeline and Development 2Q 2023 Operating Expenses Growth of 27% versus 2Q 2022 → The increases of $27.0 million in R&D expenses was primarily due to: • Continuous research and development activities in cilta- cel, including higher patient enrollment for Phase 3 clinical tria
Slide 13: Outlook: 2023 and Beyond
Outlook: 2023 and Beyond NEAR-TERM GOALS LONG-TERM GROWTH STRATEGY → Increase manufacturing capacity and efficiency → Focus on unmet medical needs in hematology/oncology → Complete enrollment of CARTITUDE-5 → Develop therapies with transforming potential → Initiate enrollment of CARTITUDE-6 → Increa
Slide 14: Ghent Facility
Ghent Facility LEGEN BIOTE cH
Slide 15: Q&A
Q&A Ying Huang, Ph.D. Lori Macomber Chief Executive Officer Chief Financial Officer Guowei Fang, Ph.D. Steve Gavel Chief Scientific Officer & Head of SVP of Commercial Development, Business Development US and Europe 15 This presentation is for investor relations purposes only - Not for product promo
Slide 16: Thank you!
Thank you! 16 This presentation is for investor relations purposes only - Not for product promotional purposes